Home » Stocks » EXEL

Exelixis, Inc. (EXEL)

Stock Price: $21.66 USD -0.30 (-1.37%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $21.67 +0.01 (0.05%) Feb 26, 6:40 PM
Market Cap 6.76B
Revenue (ttm) 987.54M
Net Income (ttm) 111.78M
Shares Out 308.27M
EPS (ttm) 0.35
PE Ratio 61.89
Forward PE 54.05
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $21.66
Previous Close $21.96
Change ($) -0.30
Change (%) -1.37%
Day's Open 22.00
Day's Range 21.44 - 22.29
Day's Volume 1,764,646
52-Week Range 13.67 - 27.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 days ago

The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed...

Business Wire - 2 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (C...

Business Wire - 1 week ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer will participate in a fire...

The Motley Fool - 1 week ago

You don't need a mountain of cash to effectively build wealth on Wall Street.

Other stocks mentioned: JUSHF, SBUX
Benzinga - 1 week ago

Exelixis Inc (NASDAQ: EXEL) announces final data from Phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozanti...

Benzinga - 1 week ago

Exelixis Inc (NASDAQ: EXEL) has reported new data from the Phase 2 (PAPMET) study evaluating CABOMETYX (cabozantinib) compared with Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in patients with...

Other stocks mentioned: PFE
Business Wire - 2 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 2 results for CABOMETYX® (cabozantinib) compared with sunitinib, the current preferred therapy ac...

Business Wire - 2 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), inc...

Zacks Investment Research - 2 weeks ago

Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.

Zacks Investment Research - 2 weeks ago

Exelixis (EXEL) delivered earnings and revenue surprises of 200.00% and -0.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Exelixis (NASDAQ:EXEL) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 46.15% over the past year to $0.14, which be...

Business Wire - 2 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2020 and provided an update on progress toward achieving k...

Business Wire - 2 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology's 2021 Genitourinary Cance...

Benzinga - 2 weeks ago

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) have announced updated data from Phase 3 CheckMate 9ER trial, evaluating the combination of former's Opdivo (nivolumab) and ...

Other stocks mentioned: BMY
Business Wire - 2 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX® (cabozantinib) activity in brain metastases in patie...

Zacks Investment Research - 2 weeks ago

Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.

Business Wire - 3 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer will participate in a fire...

Zacks Investment Research - 3 weeks ago

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 weeks ago

ALAMEDA, Calif., SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utili...

The Motley Fool - 4 weeks ago

Growth stocks have run circles around value stocks for more than a decade, and that trend is likely to continue.

Other stocks mentioned: AZN, DDOG, EVER
Business Wire - 1 month ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2020 financial results will be released on Wednesday, February 10, 2021 af...

Zacks Investment Research - 1 month ago

Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.

Business Wire - 1 month ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced initiation of the first-in-human phase 1 trial evaluating the safety, tolerability, pharmacokinetics and prelimi...

The Motley Fool - 1 month ago

The regulator's nod represents an important expansion for the drug.

Business Wire - 1 month ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for patients with advanced r...

The Motley Fool - 1 month ago

These companies offer the perfect blend of growth and value.

Other stocks mentioned: CRLBF, PING, SSRM, WTM
The Motley Fool - 1 month ago

Buying and holding innovative businesses is a time-tested way to build wealth.

Other stocks mentioned: FSLY, ISRG, OGI, V
Seeking Alpha - 1 month ago

Exelixis, Inc. (EXEL) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Zacks Investment Research - 1 month ago

Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

Business Wire - 1 month ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidan...

The Motley Fool - 1 month ago

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

Other stocks mentioned: NVAX, VRTX
The Motley Fool - 1 month ago

Bargains are plentiful for value investors in the new year.

Other stocks mentioned: AUY, TEVA, WBA, WFC
Business Wire - 1 month ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate ...

The Motley Fool - 1 month ago

Here's your prescription for huge returns in the upcoming year.

Other stocks mentioned: JUSHF, TDOC
The Motley Fool - 2 months ago

These high-growth companies are big-time bargains for opportunistic investors.

Other stocks mentioned: PING, VRTX
Zacks Investment Research - 2 months ago

Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.

The Motley Fool - 2 months ago

Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused prod...

Business Wire - 2 months ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with ...

The Motley Fool - 2 months ago

Each of them should enjoy strong sales growth in 2021 and beyond.

Other stocks mentioned: NVAX, VRTX
Zacks Investment Research - 2 months ago

Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.

Business Wire - 2 months ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigene's novel CDK7 inhibitor under the comp...

Zacks Investment Research - 2 months ago

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) to...

Other stocks mentioned: ZYME
Seeking Alpha - 2 months ago

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)

Other stocks mentioned: EVR
Business Wire - 3 months ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and co...

The Motley Fool - 3 months ago

You don't need to start with a fortune to build wealth on Wall Street.

Other stocks mentioned: AUY, JUSHF, SIRI
Business Wire - 3 months ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual invest...

Seeking Alpha - 3 months ago

Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Stifel 2020 Virtual Healthcare Conference (Transcript)

Seeking Alpha - 3 months ago

Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

Other stocks mentioned: CS
Zacks Investment Research - 3 months ago

Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.

About EXEL

Exelixis, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including M... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2000
Stock Exchange
NASDAQ
Ticker Symbol
EXEL
Full Company Profile

Financial Performance

In 2020, Exelixis's revenue was $987.54 million, an increase of 2.04% compared to the previous year's $967.78 million. Earnings were $111.78 million, a decrease of -65.18%.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Exelixis stock is "Buy." The 12-month stock price forecast is 31.17, which is an increase of 43.91% from the latest price.

Price Target
$31.17
(43.91% upside)
Analyst Consensus: Buy